EditorialLove it or Lev it: Levalbuterol for Severe Acute Asthma—for Now, Leave It
References (26)
- et al.
Salbutamol treatment of acute severe asthma in the ED: MDI versus hand-held nebulizer
Am J Emerg Med
(1998) - et al.
The safety and efficacy of nebulized lev albuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients
J Allergy Clin Immunol
(1999) - et al.
Low-dose lev albuterol in children with asthma: safety and efficacy in comparison with racemic albuterol
J Allergy Clin Immunol
(2001) - et al.
Comparison of racemic albuterol and lev albuterol for treatment of acute asthma
J Pediatr
(2003) - et al.
Clinical efficacy of racemic albuterol versus lev albuterol for the treatment of acute pediatric asthma
Ann Emerg Med
(2005) - et al.
Comparison of lev albuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial
J Emerg Med
(2005) - et al.
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial
Lancet
(2004) Expert Panel Report: guidelines for the diagnosis and management of asthma
(1991)Expert Panel Report 2: guidelines for the diagnosis and management of asthma
(1997)Expert Panel Report 2: guidelines for the diagnosis and management of asthma: update on selected topics 2002
(2002)
Expert Panel Report 3: guidelines for the diagnosis and management of asthma
(2007)
National surveillance for asthma: United States, 1980-2004
MMWR Surveill Summ
(2007)
Incremental direct expenditure of treating asthma in the United States
J Asthma
(2009)
Cited by (7)
Evaluation of efficacy of nebulized low molecular weight heparin as an adjunctive extra treatment for acute mild-moderate asthma attack; a randomized clinical trial study
2021, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :Specifically, severe asthma attacks contribute to a higher amount of exacerbations, use of health care resources, and expenditure [2], which reaches the incidence of hospital admissions by almost 50% [3]. It is recommended that high-dose β2 agonists, inhaled anticholinergics, and oral corticosteroids treat acute exacerbations [4–7], which are not always successful [8] due to resistance of 30% of patients [9]. The often delayed response to corticosteroids is also impacted by β2 adrenoreceptor gene polymorphism [10], and gene polymorphisms [11,12].
Bronchodilatory effects of B-type natriuretic peptide in acute asthma attacks: A randomized controlled clinical trial
2020, Advances in Respiratory MedicinePrinciples of Lung Therapeutics
2013, Nursing Care in Pediatric Respiratory Disease
Copyright © 2009 Elsevier Inc. All rights reserved.